S ome 10 years ago, numerous studies in different tumor and mouse models have established that transfection of cytokine genes such as IL-2, -4, -7, -10, -12, GM -CSF, or INF into tumor cell lines can protect mice against inoculation with these modified autologous cells, and in some situations, protection against later challenge with nonmodified cells or even rejection of established tumors was achieved 1 -6 (reviewed in Ref. [ 7] ). Meanwhile, more than 60 clinical protocols worldwide have been designed to augment immune response against cancer by cytokine transduction, mostly in the autologous setting. 8 However, the administration of cytokine-engineered autologous tumor cells to patients is hampered by several major drawbacks. The establishment of autologous tumor cell lines and their transfection with cytokines is a time -consuming, laborious, and expensive procedure that is frequently unsuccessful. In addition, genetically modified tumor cells from different patients may vary in terms of level and stability of cytokine expression and other molecular properties, and make comparison of clinical and biological effects difficult. Roth et al 9 therefore used cytokine -secreting allogeneic and xenogeneic cell lines to overcome these limitations and showed that coadministration of such cells with syngeneic tumor cells could control tumor growth in several mouse and rat models mainly through the activation of natural killer ( NK ) cells.
To test this immunotherapy strategy in a situation that mimics more closely the biology of human tumors, we have produced a genetically modified monkey fibroblast cell line secreting high levels of human IL -2 ( Vero -IL -2 ) to treat spontaneous fibrosarcomas and melanomas of domestic animals. Using these xenogeneic, IL -2 -secreting cells, we demonstrated in a controlled study in more than 60 cats and dogs that repeated adjuvant injections of the engineered cells into the tumor bed after surgery and local irradiation substantially improved disease-free and overall survival in the treated animals compared to controls treated by standard therapy alone. 10 On the basis of these data, we initiated a clinical gene therapy study in nine patients with advanced solid tumors using intratumoral injection of Vero -IL-2 cells (TG2001 ). Cohorts of three successive patients were treated repeatedly with 5Â10 5 , 5Â10 6 , or 5Â10 7 Vero -IL -2 cells. Treatment was well tolerated and one patient with soft -tissue sarcoma in the lowest dose group showed a more than 90% and more than 50% reduction of the volume of two distant, noninjected metastases, lasting for 29 + and 26 months, respectively. Four other patients showed stabilization of their disease for 3 to 9 months, among whom was a patient with melanoma who developed marked vitiligo. 11 Low toxicity and histological remission in two patients were also seen in an independent second phase I study of TG2001, mainly including patients with breast cancer. 12 As a continuation of these encouraging preclinical and phase I data, we started a multicentric randomized phase II study of Vero -IL -2 cells in 28 patients with metastatic melanoma, the results of which are described in this report.
Patients and methods

Study design
Two French (Paris, 1 patient; Nantes, 6 patients ) and five Swiss (Zürich, 10 patients; Basel, 5 patients; Locarno, 3 patients; Geneva, 2 patients; St. Gallen, one patient ) centers participated in the study. The total number of patients planned to be enrolled was 28, randomized between two dose levels.
Inclusion criteria (partial list ) were as follows: patients between 18 and 70 years old with histologically proven metastatic melanoma; one tumor site had to measure at least 2 cm in diameter, accessible for intratumoral administration of study drug either directly or under ultrasound guidance; performance status between 0 and 1 on the ECOG scale; minimum estimated life expectancy of 3 months; total lymphocyte count greater than or equal to 7.5Â10 8 /L.
Patients
Twenty -eight Caucasian patients, 14 male and 14 female, were enrolled in the study in seven centers. All patients were outpatients with histologically proven metastatic melanoma. Fourteen patients were randomized to the lower dose group (5Â10 5 cells) and 14 patients to the higher dose group (5Â10 6 cells ). The patients' mean age was 57.0 years (range 29-71 years ), the mean weight was 74.4 kg (range: 40.0-115.0 kg), and the median ECOG performance status at baseline was 0 (range: 0-2; one patient initially defined as ECOG 1, then redefined as ECOG 2, and considered as minor protocol violation) (see Table 1 ).
The primary disease was not resected in two patients (5Â10 5 cells treatment group ) and never detected in one patient (5Â10 6 cells treatment group ). Half of the patients had more than three metastatic sites, the most frequently being lymph nodes (21 patients; 75% ), skin ( 19 
Study drug administration
Upon satisfaction of all the inclusion and exclusion criteria, the patients were randomized to receive either 5Â10 5 or 5Â10 6 cells. Randomization was stratified by site, and a Cancer Gene Therapy
Gene therapy of melanoma with IL-2-transfected xenogenic cells C Rochlitz et al block randomization with groups of four patients was used. The product was injected directly into one selected malignant lesion, using ultrasound guidance when necessary. The same tumor site was used for administration of all three doses of a cycle. A treatment cycle consisted of three injections on days 1, 3, and 5. The first four treatment cycles were administered at 4 -week intervals, later cycles at 8 -week intervals. Treatment had to be stopped if severe toxicity occurred or as soon as progressive disease was documented.
Tumor assessment
The tumor site chosen for tumor evaluation had to be measurable by a reproducible imaging modality [chest X -ray, computed tomography (CT ), magnetic resonance imaging ( MRI ), or ultrasound ], or by physical examination, if the lesion was located in the skin. The tumor was assessed at baseline, and then at 2 -month intervals until progression. Tumor response was scored according to the standard WHO criteria for complete response ( CR ), partial response ( PR ), minimal / minor response ( MR), stable disease ( SD ), or progressive disease (PD ). SD was defined as no remission or progression for at least 8 weeks.
Safety parameters
Patients were monitored for adverse events (AEs ) throughout the study. Clinical AEs were graded according to the WHO classification and standard laboratory parameters were graded according to the NCIC -CTC classification.
Specific biological parameters, including immunology
Blood samples for immunological evaluation were taken at baseline, on days 1 and 5 of each cycle, and at the end of the study. Patients were assessed for antibody response to Vero cells by ELISA ( IgM and IgG ). The plasma cytokines IL -2, soluble IL -2 receptor, IL -6, and TNF were detected by commercially available ELISA kits ( R&D Systems ).
Immune and inflammatory cell activity inside the injected tumors was measured by semiquantitative RT-PCR using RNA extracted from tumor biopsies obtained at days 0 and 4, after injection of Vero -IL -2. mRNA levels of the TH1 cytokines IL-2 and INF (''cellular type immune response'' ) and of the TH2 cytokines IL -4 and IL -10 ( ''humoral type immune response'') were measured using Quantitative Real-Time PCR ( TaqMan 1 on an ABI Prism 1 7700 sequence detector, PE Applied Biosystems, Foster City, CA ). Reactions were done in triplicate and theoretical threshold cycle (C t ) values were calculated by the built -in software. RNA amounts were standardized by subtracting the C t values obtained for the cytokine target genes from that of two consistently expressed reference genes, GAPDH and -actin, on the same sample as described previously. 13 Results for both reference genes were comparable. Endogenous IL -2 mRNA, mainly produced by activated T cells within the tumor, was distinguished from IL -2 produced by Vero cells by use of specific primers. Because these assays are semiquantitative, only differences of at least 3 -to 4 -fold between day 0 and day 4 were considered significant.
Results
Drug exposure
All 28 patients received at least three injections of study drug ( = 1 cycle ), and at both dose levels, 6 patients received at least three treatment cycles ( = 9 injections). The mean duration of drug exposure was 62.6 days ( range 5-253 days ) for the 5Â10 5 cells group and 63.7 days ( range: 5-145 days ) for the 5Â10 6 cells group. The mean number of treatment cycles administered was 2.9 for both treatment groups (range 1-7 for the 5Â10 5 cells group, and 1 -6 for the 5Â10 6 cells group; see Table 2 ).
Efficacy
None of the patients achieved a confirmed CR, PR, or MR. Fourteen patients had SD as best overall assessment during the study (5Â10 5 cells: 6 patients, 5Â10 6 cells: 8 patients ). One patient had a PR at the first evaluation, but showed PD 18 days later and was thus rated as SD as best response ( = nonconfirmed PR ). Nineteen (68% ) patients were withdrawn from the study before cycle 4 due to disease progression.
Two patients, one from each group, died due to disease progression 31 days and 12 days after last study drug injection, respectively. Eighteen other patients died during follow -up, i.e., more than 1 month after end of treatment (5Â10 5 cells group: 7 patients; 5Â10 6 cells group: 11 patients ). Deaths occurred between 43 and 313 days after the last study drug injection and were related to PD except for two patients, whose deaths were due to unknown reasons. All deaths were unrelated to study treatment.
Safety
All 28 patients enrolled in the study were included in the safety analysis. Twenty -six (93% ) patients experienced at least one AE and 19 (68% ) patients had AEs considered as possibly or probably related to the study drug ( see Table 3 ).
The most frequently reported AEs ( related and nonrelated) were: general disorders such as fatigue, asthenia, fever, influenza -like conditions: 22 patients (79% ); administration site conditions: 22 patients (79% ); gastrointestinal disorders, 13 patients (46% ); and skin and subcutaneous Cancer Gene Therapy
Gene therapy of melanoma with IL-2-transfected xenogenic cells C Rochlitz et al tissue disorders, 11 patients (39%). The most frequently observed AEs probably related to the study drug were injection site erythema (25% ), other injection site reactions ( 25% ), and pyrexia (25%). Conditions leading to treatment discontinuation, namely deterioration of general health condition, asthenia, cachexia, bone pain, and anxiety occurred in three patients (11% ), and were considered to be related to the underlying disease.
Three patients had a grade 3 AE considered as possibly related to study drug. One patient reported erythematous inguinal left lymph nodes ( erythema 15Â7 cm ) on study day 54, diminishing to mild intensity on day 59 before completely resolving on day 97. One patient reported left retro-auricular ulcerations (treatment injection site ) on day 68, ongoing until death on day 170; and one patient had chills on day 60, the day following the second injection of the third cycle. Chills resolved spontaneously within less than 24 hours.
Nine patients ( 5Â10 5 cells: 5 patients; 5Â10 6 cells: 4 patients ) reported a total of 11 serious AEs, only one of which, a mild, spontaneously resolving pancreatitis, was considered as possibly related to study medication. All NCIC -CTC grade 3 or grade 4 abnormal laboratory values were considered by the investigators as either not clinically significant (some of the grade 3 abnormalities ), or disease related.
In summary, intratumoral administration of TG2001 was generally well tolerated, and there were no differences in AEs between the two treatment groups.
Biological analyses
Immune response to Vero cells. 
Systemic cytokines
Plasma content of IL -2 was measured, and highly variable day 0 values were observed. No clear pattern of IL -2 plasma level changes was seen during treatment and there was no correlation with any of the clinical or biological endpoints of the study. Soluble IL-2 receptor can be produced in response to IL -2 and can neutralize the biological activity of IL-2. In all tested patients, levels of soluble IL -2 receptor were within the range found in normal plasma. Similarly, levels of the inflammatory cytokine IL -6 also fluctuated around the normal range. The only notable increase was found in one patient, whose IL-6 levels went from 12 to 36 pg /mL between days 0 and 4 of the first cycle. This patient was later withdrawn from the study because of disease progression. High levels of circulating IL-6 have been correlated with poor prognosis in other cancers, notably breast cancer. Another inflammatory cytokine, TNF was also measured, and a burst of TNF in the plasma of two patients was noted at day 57. Values had gone back to baseline at the time of the patients' last blood samplings on day 89 and day 150, respectively.
Immune cell activity in tumor biopsies
Th1 response. Some increase (2 -to 3 -fold ) of endogenous IL -2 levels was observed in 7/ 15 evaluable patients, but was significant only in patients #307 and 602 (second cycle ); a decrease was seen in three patients. In addition, the baseline variation of IL-2 levels was such that this overall increase of IL -2 did not reach statistical significance. mRNA from 21 patients was evaluable for IFN expression, in five patients from more than one cycle. Seven of the patients ( #101, 102, 201, 203, 204, 308, and 602) had evidence of a notable increase, two patients of a significant decrease in IFN gene expression upon injection of Vero -IL -2. Four of the five patients from whom several cycles could be analyzed showed a consistent pattern of INF regulation between cycles, whereas only patient #201 showed no change after the first injection, but a marked increase after the third. Again, the overall response of INF expression to injection of Vero -IL -2 cells was not significant. Th2 response. Th2 cytokine expression was also analyzed. IL -4 gene expression was evaluable in biopsies from 25 of the 28 treated patients. Biopsy RNA from 14 of 25 patients showed a dramatic increase in IL -4 gene expression (3 -to >100-fold ) with, however, some inconsistencies between cycles. Eight samples from seven patients showed a much less important decrease in IL -4 gene expression after treatment. Because of this large variation in expression levels, the increase of IL -4 for the whole group did not reach 
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Gene therapy of melanoma with IL-2-transfected xenogenic cells C Rochlitz et al statistical significance. IL -10 gene expression was evaluable for the same 25 patients as for IL -4. Interestingly, the IL -10 gene expression changes were strikingly similar to those of IL -4 in the different patients and over the different cycles, with the exception of patients #203 and 501. However, the increase of IL -10 for the whole group almost reached statistical significance (t test; P= .054 ).
In conclusion, there were no strong patterns of cytokine expression changes, and there was no mutual exclusivity between Th1 and Th2 cytokine expression. However, IL -4 and IL -10 were extremely closely coregulated, and their expression seemed to be more stimulated than that of IL -2 and INF by the intratumoral Vero -IL -2 injections, possibly defavoring a cellular-type immune response in our patients.
Discussion
Studies using animal models have demonstrated that transduction of genes encoding different cytokines into tumor cells results in a local recruitment of inflammatory cells that in turn can inhibit tumor growth. This was often accompanied by tumor antigen priming of the host immune system, which becomes resistant to subsequent challenge by the parental, untransduced tumor. Gene -transduced tumor cells have therefore been widely used as vaccines to prevent tumor growth in experimental models. However, the efficacy of this approach in treating established tumors has been shown in only a few animal models. 7, 8 Nevertheless, clinical studies were initiated on the basis of this rationale, and vaccination with cytokine gene -transduced autologous or allogeneic tumor cells was carried out in patients with melanoma, 14 -17 neuroblastoma, 18 -20 renal cell cancer, 21 prostate carcinoma, 22 multiple myeloma, 23 glioma, 24, 25 and colorectal cancer. 26 In these protocols, only 20-30% of patients developed a T cell -specific antitumor response, and only a minority of patients ( < 10% ) had a clinical minor or partial response (reviewed in Ref. [8 ] ).
To our knowledge, the only studies using xenogeneic, cytokine-transfected cells ( Vero -IL -2 cells ) to treat patients with different solid tumors have been performed and published by our group.
11,12 Because we used xenogeneic fibroblasts, not tumor cells, to express the human IL -2, the transfected cells had to be injected intratumorally to make up for the absence of tumor-specific antigens on the cellular construct. The encouraging phase I activity of Vero -IL -2 in different solid tumors led to the randomized, multicentric phase II study of intratumoral injection of 5Â10 5 or 5Â10 Vero -IL -2 cells in 28 patients with metastatic melanoma reported here. Our study confirms the favorable toxicity profile of Vero -IL -2 treatment seen in the two phase I studies reported previously. 11, 12 In addition, although we did not see a single PR or CR, 14 of 28 patients ( 50% ) achieved SD lasting for up to 4 months. This observation can by no means be taken as proof of the clinical efficacy of Vero -IL -2. However, in a heavily pretreated population of melanoma patients, all progressing before start of gene therapy, this result is at least compatible with a marginal effect of Vero -IL -2 on clinical outcome.
Nevertheless, the outcome of our specific approach to cytokine gene therapy of cancer is clearly disappointing. In addition to the obvious argument that the treatment might have been too late in the course of the disease in these patients with far advanced, heavily pretreated melanoma, there are several potential explanations for the apparent lack of activity of Vero-IL -2.
First, it is conceivable that metastatic melanoma is less amenable to Vero -IL -2 immunotherapy than other malignancies. In fact, the most impressive clinical activity of TG2001 in the two phase I studies we performed was seen in a patient with leiomyosarcoma, 11 and in the preclinical evaluation in large domestic animals, the benefit of the product was somewhat more pronounced in cats with sarcoma than in dogs with melanoma. 10 However, we chose melanoma for our phase II study because it is the human malignancy considered to be most readily influenced by immunotherapeutic strategies, 7 and it is unlikely that an immunotherapy with so little effect in melanoma should be very efficacious in other tumors.
Second, it can be questioned if the xenogeneic model we used provides an optimal immunological microenvironment to induce a tumor-specific immune response. Comparisons between autologous and allogeneic approaches to gene therapy with cytokine-transfected tumor cells have shown that allogeneic cells do not preferentially induce an antiallo HLA response rather than an antitumor immune response. 8 Indeed, in vitro and in vitro stimulation of patient lymphocytes with allogeneic tumor cells does not prevent or reduce recognition of autologous tumor antigens. On the contrary, a preferential recognition of tumor antigens may occur, 27 -29 a conclusion also supported by animal studies. 30 A direct comparison of vaccination with autologous versus allogeneic cytokine-transduced cells has not been performed in patients. However, different trials performed by the same group in neuroblastoma patients using IL-2-transduced autologous or allogeneic neuroblastoma cells suggest a certain advantage for the autologous vaccine in terms of both immunological and clinical response. 19, 20 However, the relatively low efficacy of these vaccines in patients with malignomas in general forbids any firm conclusions on eventual differences in activity of the autologous versus. the allogeneic approach.
The concept of ''cross-priming'' describes the uptake and processing of released antigens by professional antigenpresenting cells ( APCs ) which travel to lymph nodes where they induce a specific MHC class I-restricted T-cell response. 31 Theoretically, this concept should apply to the allogeneic model of immunotherapy by cytokine transfection, but also to our approach of intratumoral injection of xenogeneic cytokine -secreting cells. Interestingly, in a mouse model, adenoviral transfer of xenogeneic MHC class I genes was much more efficient in the inhibition of tumor growth and induction of a specific antitumor T-cell response than transfer of allogeneic MHC class I molecules, 32 underlying the potential of the xenogeneic approach in tumor immunology. However, despite these findings and our encouraging results of Vero -IL -2 treatment in large do-mestic animals, 10 it is conceivable that the strong nonspecific immune stimulus of xeno -antigens in the presence of high amounts of IL-2 leads to a ''deviation of the immune response'' rather than to a specific antitumor reaction, thus explaining our failure to induce clinical responses in melanoma patients treated with Vero -IL -2.
Third, it can be speculated if IL -2 was the best cytokine to be used in the xenogeneic model. Studies in animals have shown that the optimum cytokine depends on the tumor model under evaluation, and although some authors have strongly advocated GM -CSF as the best cytokine, e.g., in the B16 melanoma model, 6 others described IL -2 as more effective than GM -CSF in a low immunogenic mammary carcinoma, 33 and in several recent studies, IL -12 seemed to be superior to all other cytokines in different mouse models. 34 Preliminary clinical reports on IL-12-transduced tumor vaccines are encouraging, 35 and it might be interesting to test our xenogeneic approach with this specific cytokine.
Fourth, an important point to consider in IL -2 -expressing cellular vaccine studies is the question of a possible doseresponse relationship. Schmidt et al 36 observed a strong correlation between the rate of IL -2 production and the protection efficiency of murine S91 melanoma cell vaccines. Best immunization was achieved with vaccines producing medium IL -2 levels of 1000 -3000 U per 10 5 cells per day. Reduced IL -2 production evoked a corresponding decline in the number of successfully treated animals. Unexpectedly, when IL -2 expression was raised to high levels of 5000 -7500 U per 10 5 cells per day, protection was completely absent because of impaired generation of tumor-specific cytotoxic T lymphocytes. 36 Interestingly, in our two phase I studies, the most important clinical and immunological responses occurred at the two lower dose levels using Vero -IL -2 cells producing relatively high amounts of 14,000 U per 10 5 cells per day. 11, 12 Although our results in humans cannot be quantitatively compared to those by Schmidt et al for various biological and technical reasons, it can be speculated that the ''bell -shaped dose response curve'' to IL -2 described in animals might indeed also play a role in clinical trials in humans. For that reason, we had designed our phase II study as a randomized comparison of two dose levels, but the lack of efficiency of TG2001 in our study makes any conclusion on a dose -response effect of IL -2 impossible.
Finally, our observation on intratumoral cytokine mRNA expression before and after treatment deserves some comment. We could not detect a significant increase in the expression of the type 1 cytokines INF and IL -2 after treatment with Vero-IL -2. However, approximately 60% of the patients showed dramatic (3 -to >100 -fold ) increases in mRNA expression of both type 2 cytokines, IL -4 and IL -10. It has been shown in animal models that immune T cells that secrete type 2 cytokines ( e.g., IL -4, IL -10 ) have a suppressive effect on antitumor reactivity when used in adoptive immunotherapy, whereas secretion of the type 1 cytokines facilitates tumor regression. 37 Similarly, in an elegant study in the DBA /2 mouse model, Song et al 38 showed that immunity elicited by DNA vaccination against CEA can be biased to a protective type (high Th1 and CTL activity ) or nonprotective type ( high Th2 and low CTL activity ) by intramuscular coinjection of the respective cytokine -expressing plasmids. 38 Although the exact role of types 1 and 2 responses in human tumor immunology remains to be defined, a CTL type of immune response seems to be associated with Th1 cytokines, whereas Th2 cytokines are more often associated with antibody production. 39 It is tempting to speculate that intratumoral treatment with Vero -IL -2 caused a local shift toward a humoral -type rather than a cellular-type immune response, thereby decreasing the effective overall antitumor immunity, and thus explaining the disappointing clinical activity of TG2001.
In conclusion, intratumoral injection of xenogeneic IL-2-producing cells lead to no partial or complete response in 28 patients with metastatic melanoma. Possible explanations for the low activity of treatment include the choice, dosage, or schedule of the cytokine used, a deviation of the immune response through xenogeneic antigens, and the induction of a humoral type 2 rather than a cellular type 1 immune response. In the light of recent reports on peptide -based treatment strategies in melanoma, which achieved induction of T-cell responses in the majority of patients and, most importantly, clinical response rates of 28 -42%, 40 -42 it seems unlikely that intratumoral injection of Vero -IL -2 cells will turn out to be a competitive treatment strategy in metastatic malignant melanoma.
